null - FindTrial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-002298-20-FR

Enrollment

150

Registered

2017-12-05

Start date

2018-01-23

Completion date

Unknown

Last updated

2022-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.0 Level: LLT Classification code 10062893 Term: Rhizarthrosis System Organ Class: 100000004859

Interventions

Trade Name: Diprostène 7mg Product Name: DIPROSTENE Pharmaceutical Form: Solution for injection Other descriptive name: BETAMETHASONE DIPROPIONATE Concentration unit: mg milligram(s) Concentration typ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 90

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactAUZANNEAU Lucie

Centre Hospitalier Départemental Vendée

lucie.auzanneau@chd-vendee.fr+330251446380

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026